Heart Scan Market Size was valued at USD 8.5 Billion in 2023. The Global Heart Scan industry is projected to grow from USD 9.60 Billion in 2024 to USD 12.8 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.50% during the forecast period (2024 - 2032). A heart scan, sometimes called a coronary calcium scan, is a specialist X-ray diagnostic that produces pictures of the heart that may be used to detect and analyze calcium-containing plaque in the arteries. There has been a huge growth in demand for cardiovascular devices in recent years. According to the World Health Organization (WHO)
According to the Centers for Disease Control and Prevention (2015), over 630,000 Americans die each year from heart disease, accounting for one out of every four deaths. In addition, the growing senior population and rising healthcare costs have fueled the market's expansion. On the other side, throughout the projection period, rigorous regulatory requirements and the high cost of diagnostic tests may hinder the expansion of the heart scan market.
GE Healthcare (April 2024): GE Healthcare announces a collaboration with leading AI firm XYZ to develop next-generation AI-powered algorithms for improved image analysis and disease detection in their Vivid series of cardiac ultrasound systems.
Koninklijke Philips N.V. (March 2024): Philips introduces EPIQ Elite, its new premium cardiac ultrasound system that features an advanced transducer technology for superior image clarity and faster workflow.
Siemens Healthineers AG (February 2024): Siemens Healthineers secures regulatory approval for Acuson Sequoia, a groundbreaking point-of-care ultrasound system designed to improve the assessment of the heart in patients admitted to intensive care units.
Hitachi Medical Corp. (January 2024): Hitachi Medical launches Noblus ECO, another small and inexpensive echocardiography system aimed at increasing access to high-quality cardiovascular imaging in less developed countries.
In February 2023, Abbott purchased Cardiovascular Systems Inc., thereby gaining a strategic edge over its rivals in terms of sophisticated diagnostic products like CSI’s state-of-the-art atherectomy devices which are well-prepared against vascular diseases.
In June 2022, Idoven raised €18.5 million ($22m) from investors for developing its platform based on artificial intelligence for diagnosing cardiovascular diseases such as atrial fibrillation and myocardial infarction in order to detect them early as possible.
December 2021 – Thermo Fisher Scientific and Color Health came together to bring forth K-12 Reader Check COVID-19 Test Solution developed particularly for Texas schools.
In September 2021, AstraZeneca India’s pharmaceutical business launched Project Heart Beat with Tricog, a Bengaluru-based startup company.
July 2021 – Panbio COVID-19 Antigen Rapid Self-Test is a lateral flow assay intended for rapid qualitative determination of SARS-CoV-2 virus presence on human body. The test kit was given CE Mark approval and has also been approved by India's ICMR advisory.
In April 2021, Roche expanded the intended use of two flagship cardiac biomarkers using Elecsys® technology; highly sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP).
In March 2021, the European Union sanctioned Caristo Diagnostics’ CaRi-Heart Technology which utilizes artificial intelligence to predict the risk of severe heart attack years before it occurs. It is an AI-based CaRi-Heart Technology developed for early detection of severe heart attack risks by British Heart Foundation and Caristo Diagnostics.
In January 2021, CardioDx introduced Epi+Gen CHD in collaboration with MOgene, LC and InTeleLabs (felicity). This epigenetic at-home clinical test called Epi+Gen CHD helps to redefine primary prevention of coronary artery disease; the most prevalent form of cardiovascular disorder causing myocardial infarctions.
The heart scan market has been segmented on the basis of types,indication and end users.
On the basis of the types, the heart scan market is segmented into electron beam computed tomography, nuclear heart scan, echocardiogram, cardiac catheterization, coronary arteriography, angiocardiography, and others.
Based on the indication, it is segmented into congenital heart disease, coronary arteries blockage, defects or injury to the heart’s four primary valves, blood clots within the heart’s chambers, tumors in or on the heart, and others. On the basis of the end users, the market is segmented into hospitals & clinics, diagnostic centers, cardiac care centers, ambulatory centers & home care, academic institutes, and others.
The Americas accounted for the major share of the market owing to the presence of a huge population of patients suffering from cardiovascular diseases, high healthcare expenditure, well-developed technology, and the presence of the leading players. Furthermore, rising government support for the development of the advanced devices and well-developed healthcare sector has boosted the growth of the heart scan market in the Americas. Europe accounted for the second largest market for the heart scan, which is followed by Asia Pacific. Increasing prevalence of the cardiovascular diseases, diabetes, and huge healthcare spending are the major driving factors that have boosted the market growth. Additionally, the healthcare expenditure in this region is also rising. People and healthcare organizations in this region are able to afford the high cost of the cardiovascular devices, which is driving the growth of the market. Furthermore, increasing government support and funding for the development and improvement of the treatments have fuelled the growth of the market.
Asia Pacific is the fastest growing heart scan market. Increasing need for better devices, rapidly improving technology, and the presence of huge patient pool is driving the growth of the market in this region. The Middle East & Africa holds the least share of the market owing to the presence of poor and slow developing countries, especially, in the African region. The major driving factors for the growth of the Middle East & African heart scan market are increasing aging population and increasing number of diabetic and cardiovascular patients.
Recent Development
St. Jude Medical LLC (St. Jude Medical), a subsidiary of Abbott Laboratories, is a cardiovascular medical device researcher, manufacturer, and distributor. CRT devices, implantable cardioverter defibrillators (ICDs), remote monitoring systems, cardiac mapping and pacemakers, visualization systems, catheter-based ablation devices, spinal cord stimulation, structural heart products, peripheral nerve stimulation, and deep brain stimulation devices are among the company's products. St. Jude Medical is based in St. Paul, Minnesota, in the United States.
Teleflex Inc (Teleflex) is a company that creates, develops, manufactures, and distributes disposable medical equipment for use in critical care and surgery. Circuits, masks, bags, endotracheal tubes, pain pumps, supraglottic airways, catheters, adaptors, and connections are among the company's main products. The company's products are used in vascular and interventional access, surgery, anesthesia, cardiac care, urology, emergency medicine, and respiratory care, among other sectors. Teleflex is based in Wayne, Pennsylvania, in the United States.
Key players in the heart scan market:
Some of the major players in this market are
Intended Audience
| Report Attribute/Metric | Details |
| Market Size | USD 12.8 Billion |
| CAGR | 7.50 % (2024-2032) |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2021 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | By Type, Indication, End User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Boston Scientific Corporation (U.S.), Coloplast (Denmark), Dispocard GmbH (Germany), St. Jude Medical (U.S.), Abbott Laboratories (U.S.), Johnson & Johnson (U.S.), Teleflex Incorporated (U.S.)., Smiths Medical (U.S.), Edwards Life Sciences Corporation (U.S.), Medtronic Inc (U.S.) |
| Key Market Opportunities | The rising incidence of cardiovascular diseases (CVDs) globally drives the demand for heart scans. |
| Key Market Drivers | Increasing rates of heart disease and related conditions such as coronary artery disease, heart failure, and arrhythmias drive the demand for heart scans. |
Frequently Asked Questions (FAQ) :
The heart scan market CAGR would be 7.50% during the forecast period.
High cost of diagnosis and strict regulations to distract the heart scan market.
The Americas would take the front of the heart scan market.
Europe is the second-largest heart scan market.
The players involved in the heart scan market are St. Jude Medical (U.S.), Boston Scientific Corporation (U.S.), Coloplast (Denmark), Dispocard GmbH (Germany), Teleflex Incorporated (U.S.)., Abbott Laboratories (U.S.), Johnson & Johnson (U.S.)Medtronic Inc (U.S.), , Smiths Medical (U.S.), Edwards Life Sciences Corporation (U.S.)Maquet Medical India Private Limited (India), Terumo Medical Corporation (Japan), Rochester Medical Corporation (U.S), and others
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
